Stephane Bancel
CIK 1443340 · Chief Executive Officer · last filed 2026-03-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.00B
Companies
5
Total Filings
322
Lifetime Open-Market Net
-$1.19B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MRNA | Chief Executive Officer | 15,398,477 | $63.96 | $984.89M | -$1.19B | 284 | 2026-03-03 |
| GENB | Director | 1,184,989 | $14.49 | $17.17M | $0 | 1 | 2026-03-02 |
| SYRS | Director | 47,980 | $0.00 | $19 | $0 | 2 | 2016-09-19 |
| BG Medicine, Inc. (BGMD) Delisted | Executive Chairman | 123,167 | — | — | $226.1K | 11 | 2013-11-04 |
| Targanta Therapeutics Corp. (TARG) Delisted | Director | — | — | — | $0 | 1 | 2008-08-26 |
Recent Filings · Page 30 of 33
322 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-01-23 | MRNA | Sell (S) | −15,398 | -$354.2K | EDGAR |
| 2020-01-22 | MRNA | Sell (S) | −4,850 | -$100.8K | EDGAR |
| 2020-01-21 | MRNA | Sell (S) | −11,046 | -$231.5K | EDGAR |
| 2020-01-17 | MRNA | Gift (G) | −4,989 | $0 | EDGAR |
| 2020-01-14 | MRNA | Sell (S) | −16,482 | -$333.6K | EDGAR |
| 2020-01-06 | MRNA | Sell (S) | −16,160 | -$310.4K | EDGAR |
| 2020-01-03 | MRNA | Sell (S) | −11,046 | -$215.7K | EDGAR |
| 2019-12-23 | MRNA | Sell (S) | −11,046 | -$217.5K | EDGAR |
| 2019-12-16 | MRNA | Sell (S) | −11,046 | -$204.7K | EDGAR |
| 2019-12-11 | MRNA | Other (J) | +42,132 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.